Application of a Risk Score to Identify Older Adults with Community-Onset Pneumonia Most Likely to Benefit From Empiric Pseudomonas Therapy

Christopher R. Frei, Sylvie Rehani, Grace C. Lee, Natalie K. Boyd, Erene Attia, Ashley Pechal, Rachel S. Britt, Eric M. Mortensen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Study Objective: To assess the impact of empiric Pseudomonas pharmacotherapy on 30-day mortality in hospitalized patients with community-onset pneumonia stratified according to their risk (low, medium, or high) of drug-resistant pathogens. Design: Retrospective cohort study. Data Source: Veterans Health Administration database. Patients: A total of 50,119 patients who were at least 65 years of age, hospitalized with pneumonia, and received antibiotics within 48 hours of admission between fiscal years 2002 and 2007. Patients were stratified into empiric Pseudomonas therapy (31,027 patients) and no Pseudomonas therapy (19,092 patients) groups based on antibiotics received during their first 48 hours of admission. Measurements and Main Results: A clinical prediction scoring system developed in 2014 that stratifies patients with community-onset pneumonia according to their risk of drug-resistant pathogens was used to identify patients who were likely to benefit from empiric Pseudomonas therapy as well as those in whom antipseudomonal therapy could be spared; patients were classified into low-risk (68%), medium-risk (21%), and high-risk (11%) groups. Of the 50,119 patients, 62% received Pseudomonas therapy. All-cause 30-day mortality was the primary outcome. Empiric Pseudomonas therapy (adjusted odds ratio 0.72, 95% confidence interval 0.62–0.84) was associated with lower 30-day mortality in the high-risk group but not the low- or medium-risk groups. Conclusion: Application of a risk score for patients with drug-resistant pathogens can identify patients likely to benefit from empiric Pseudomonas therapy. Widespread use of this score could reduce overuse of anti-Pseudomonas antibiotics in low- to medium-risk patients and improve survival in high-risk patients.

Original languageEnglish (US)
Pages (from-to)195-203
Number of pages9
JournalPharmacotherapy
Volume37
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Pseudomonas
Pneumonia
Therapeutics
Anti-Bacterial Agents
Mortality
Pharmaceutical Preparations
Veterans Health
United States Department of Veterans Affairs
Information Storage and Retrieval
Cohort Studies
Retrospective Studies
Odds Ratio

Keywords

  • evidence-based medicine
  • infectious disease
  • outcomes
  • pharmacy practice
  • pulmonary

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Application of a Risk Score to Identify Older Adults with Community-Onset Pneumonia Most Likely to Benefit From Empiric Pseudomonas Therapy. / Frei, Christopher R.; Rehani, Sylvie; Lee, Grace C.; Boyd, Natalie K.; Attia, Erene; Pechal, Ashley; Britt, Rachel S.; Mortensen, Eric M.

In: Pharmacotherapy, Vol. 37, No. 2, 01.02.2017, p. 195-203.

Research output: Contribution to journalArticle

Frei, Christopher R. ; Rehani, Sylvie ; Lee, Grace C. ; Boyd, Natalie K. ; Attia, Erene ; Pechal, Ashley ; Britt, Rachel S. ; Mortensen, Eric M. / Application of a Risk Score to Identify Older Adults with Community-Onset Pneumonia Most Likely to Benefit From Empiric Pseudomonas Therapy. In: Pharmacotherapy. 2017 ; Vol. 37, No. 2. pp. 195-203.
@article{bc15c5da4d4c41ac996149c9eb03636f,
title = "Application of a Risk Score to Identify Older Adults with Community-Onset Pneumonia Most Likely to Benefit From Empiric Pseudomonas Therapy",
abstract = "Study Objective: To assess the impact of empiric Pseudomonas pharmacotherapy on 30-day mortality in hospitalized patients with community-onset pneumonia stratified according to their risk (low, medium, or high) of drug-resistant pathogens. Design: Retrospective cohort study. Data Source: Veterans Health Administration database. Patients: A total of 50,119 patients who were at least 65 years of age, hospitalized with pneumonia, and received antibiotics within 48 hours of admission between fiscal years 2002 and 2007. Patients were stratified into empiric Pseudomonas therapy (31,027 patients) and no Pseudomonas therapy (19,092 patients) groups based on antibiotics received during their first 48 hours of admission. Measurements and Main Results: A clinical prediction scoring system developed in 2014 that stratifies patients with community-onset pneumonia according to their risk of drug-resistant pathogens was used to identify patients who were likely to benefit from empiric Pseudomonas therapy as well as those in whom antipseudomonal therapy could be spared; patients were classified into low-risk (68{\%}), medium-risk (21{\%}), and high-risk (11{\%}) groups. Of the 50,119 patients, 62{\%} received Pseudomonas therapy. All-cause 30-day mortality was the primary outcome. Empiric Pseudomonas therapy (adjusted odds ratio 0.72, 95{\%} confidence interval 0.62–0.84) was associated with lower 30-day mortality in the high-risk group but not the low- or medium-risk groups. Conclusion: Application of a risk score for patients with drug-resistant pathogens can identify patients likely to benefit from empiric Pseudomonas therapy. Widespread use of this score could reduce overuse of anti-Pseudomonas antibiotics in low- to medium-risk patients and improve survival in high-risk patients.",
keywords = "evidence-based medicine, infectious disease, outcomes, pharmacy practice, pulmonary",
author = "Frei, {Christopher R.} and Sylvie Rehani and Lee, {Grace C.} and Boyd, {Natalie K.} and Erene Attia and Ashley Pechal and Britt, {Rachel S.} and Mortensen, {Eric M.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1002/phar.1891",
language = "English (US)",
volume = "37",
pages = "195--203",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Application of a Risk Score to Identify Older Adults with Community-Onset Pneumonia Most Likely to Benefit From Empiric Pseudomonas Therapy

AU - Frei, Christopher R.

AU - Rehani, Sylvie

AU - Lee, Grace C.

AU - Boyd, Natalie K.

AU - Attia, Erene

AU - Pechal, Ashley

AU - Britt, Rachel S.

AU - Mortensen, Eric M.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Study Objective: To assess the impact of empiric Pseudomonas pharmacotherapy on 30-day mortality in hospitalized patients with community-onset pneumonia stratified according to their risk (low, medium, or high) of drug-resistant pathogens. Design: Retrospective cohort study. Data Source: Veterans Health Administration database. Patients: A total of 50,119 patients who were at least 65 years of age, hospitalized with pneumonia, and received antibiotics within 48 hours of admission between fiscal years 2002 and 2007. Patients were stratified into empiric Pseudomonas therapy (31,027 patients) and no Pseudomonas therapy (19,092 patients) groups based on antibiotics received during their first 48 hours of admission. Measurements and Main Results: A clinical prediction scoring system developed in 2014 that stratifies patients with community-onset pneumonia according to their risk of drug-resistant pathogens was used to identify patients who were likely to benefit from empiric Pseudomonas therapy as well as those in whom antipseudomonal therapy could be spared; patients were classified into low-risk (68%), medium-risk (21%), and high-risk (11%) groups. Of the 50,119 patients, 62% received Pseudomonas therapy. All-cause 30-day mortality was the primary outcome. Empiric Pseudomonas therapy (adjusted odds ratio 0.72, 95% confidence interval 0.62–0.84) was associated with lower 30-day mortality in the high-risk group but not the low- or medium-risk groups. Conclusion: Application of a risk score for patients with drug-resistant pathogens can identify patients likely to benefit from empiric Pseudomonas therapy. Widespread use of this score could reduce overuse of anti-Pseudomonas antibiotics in low- to medium-risk patients and improve survival in high-risk patients.

AB - Study Objective: To assess the impact of empiric Pseudomonas pharmacotherapy on 30-day mortality in hospitalized patients with community-onset pneumonia stratified according to their risk (low, medium, or high) of drug-resistant pathogens. Design: Retrospective cohort study. Data Source: Veterans Health Administration database. Patients: A total of 50,119 patients who were at least 65 years of age, hospitalized with pneumonia, and received antibiotics within 48 hours of admission between fiscal years 2002 and 2007. Patients were stratified into empiric Pseudomonas therapy (31,027 patients) and no Pseudomonas therapy (19,092 patients) groups based on antibiotics received during their first 48 hours of admission. Measurements and Main Results: A clinical prediction scoring system developed in 2014 that stratifies patients with community-onset pneumonia according to their risk of drug-resistant pathogens was used to identify patients who were likely to benefit from empiric Pseudomonas therapy as well as those in whom antipseudomonal therapy could be spared; patients were classified into low-risk (68%), medium-risk (21%), and high-risk (11%) groups. Of the 50,119 patients, 62% received Pseudomonas therapy. All-cause 30-day mortality was the primary outcome. Empiric Pseudomonas therapy (adjusted odds ratio 0.72, 95% confidence interval 0.62–0.84) was associated with lower 30-day mortality in the high-risk group but not the low- or medium-risk groups. Conclusion: Application of a risk score for patients with drug-resistant pathogens can identify patients likely to benefit from empiric Pseudomonas therapy. Widespread use of this score could reduce overuse of anti-Pseudomonas antibiotics in low- to medium-risk patients and improve survival in high-risk patients.

KW - evidence-based medicine

KW - infectious disease

KW - outcomes

KW - pharmacy practice

KW - pulmonary

UR - http://www.scopus.com/inward/record.url?scp=85012240045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012240045&partnerID=8YFLogxK

U2 - 10.1002/phar.1891

DO - 10.1002/phar.1891

M3 - Article

C2 - 28035692

AN - SCOPUS:85012240045

VL - 37

SP - 195

EP - 203

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 2

ER -